Hologic (HOLX) PT Lowered to $70 at Stephens

Stephens analyst Mason Carrico lowered the price target on Hologic (NASDAQ: HOLX) to $70.00 (from $77.00) while maintaining a Overweight rating.

The analyst commented: 'HOLX shares traded down after a disappointing F2Q25. Skeletal drove a slight revenue beat while gross margin/operating margin missed (adj. EPS beat by 1c). F3Q25 revenue/adj. EPS was guided below Street. However, looking ahead, HOLX expects breast health to return to growth in F4Q25, and easier comps and the Envision launch in 2026 should enable breast health to return to growth next year. Near-term, the lack of catalysts could keep shares range bound. However, at ~14x our FY26 EPS estimate, we feel like moderated NT growth is priced in here. For shares to work higher, top-line trends need to improve, and we see the opportunity for this to play out exiting the year. Net-net, while not a lot to get excited about near-term, we think there's likely more upside than downside over the next 12 months, but this relies on execution in breast health. Reiterate OW/Vol./PT to $70 (from $77)."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Some Glazer family members said to consider selling Manchester United plc (MANU) stake - Bloomberg
• BorgWarner (BWA) PT Raised to $95 at Wolfe Research, 'Bullish Takeaways from CEO Meetings'